Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Netherlands

Netherlands

The Netherlands is projected to see a revenue of €246.80m in the Other Vaccines market by 2024.
It is expected to experience an annual growth rate (CAGR 2024-2029) of 10.48%, leading to a market volume of €406.30m by 2029.
In global comparison, United States is anticipated to generate the highest revenue of €22,940.00m in 2024.
The Netherlands has seen a steady increase in demand for other vaccines, driven by a strong emphasis on public health and proactive immunization campaigns.

Key regions: Australia, Brazil, United Kingdom, Europe, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Other Vaccines market in Netherlands is a rapidly growing market that has seen a surge in demand over the past few years.

Customer preferences: The Dutch population has always been known for its proactive approach towards healthcare. The rising awareness about the importance of vaccinations has led to an increase in demand for Other Vaccines in the country. The government's proactive approach towards vaccination programs has also contributed to the growth of the market.

Trends in the market: The Other Vaccines market in Netherlands has witnessed a surge in demand due to the COVID-19 pandemic. The pandemic has led to an increase in awareness about the importance of vaccinations, and this has led to a surge in demand for Other Vaccines. The demand for Other Vaccines is expected to remain high in the coming years, as the government is planning to expand its vaccination programs.

Local special circumstances: The Netherlands is known for its high-quality healthcare system, which has contributed to the growth of the Other Vaccines market. The country has a well-established healthcare infrastructure, which has made it easier for vaccine manufacturers to distribute their products. The government's proactive approach towards healthcare has also contributed to the growth of the market.

Underlying macroeconomic factors: The Dutch economy has been growing steadily over the past few years, and this has led to an increase in the disposable income of the population. The rise in disposable income has led to an increase in demand for healthcare services, including vaccinations. The government's proactive approach towards healthcare has also contributed to the growth of the market. The country's stable political environment and favorable business climate have also made it an attractive market for vaccine manufacturers.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.